(By Balaseshan) Mylan Inc. (NASDAQ:MYL), a pharmaceutical company, said its subsidiary launched the generic version of Pfizer Inc.'s (NYSE:PFE) top-selling cholesterol controlling drug Lipitor.
Mylan Laboratories Ltd. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg. Mylan is shipping this product immediately.
Atorvastatin Calcium is the generic version of Pfizer's Lipitor Tablets, which are indicated as an adjunct to diet in patients with primary hypercholesterolemia and mixed dyslipidemia to reduce elevated total cholesterol, LDL, triglycerides and to increase HDL cholesterol.
[Related -Mylan, Inc. (MYL) Q3 Earnings Preview: Weak Dollar = Strong Profit?]
Earlier this month, Mylan announced the launch of the generic version of Lipitor in France, Belgium, the UK, the Netherlands and Ireland. Lipitor had U.S. sales of $8.1 billion for the twelve months ending March 31, 2012, according to IMS Health.
On Thursday, Mylan announced the launch of generic version of Roche's osteoporosis treatment Bonviva in the UK and Italy. Osteoporosis is the thinning of bone tissue and loss of bone density over time, common in older women.
On Wednesday, Mylan said its subsidiary launched the generic version of Viramune tablets to treat patients living with HIV/AIDS, after final approval from the U.S. health regulators. This expands further the reach of Mylan's global antiretroviral portfolio.
[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]
The company announced the launch of generic version of Sanofi-Aventis' (NYSE:SNY) Plavix blood thinning tablets indicated for acute coronary syndrome. Mylan's Pharmaceuticals Inc. has received final clearance from the U.S. health regulators for its ANDA for Clopidogrel Tablets USP, 75 mg and 300 mg.
MYL is trading up 0.79% at $21.80 on Tuesday. The stock has been trading between $15.49 and $25 for the past 52 weeks.